These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28461199)

  • 1. New structural formats of therapeutic antibodies for rheumatology.
    Dumet C; Pottier J; Gouilleux V; Watier H
    Joint Bone Spine; 2018 Jan; 85(1):47-52. PubMed ID: 28461199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The manufacturing considerations of bispecific antibodies.
    Underwood DJ; Bettencourt J; Jawad Z
    Expert Opin Biol Ther; 2022 Aug; 22(8):1043-1065. PubMed ID: 35771976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in antibody engineering for rheumatic diseases.
    Schmid AS; Neri D
    Nat Rev Rheumatol; 2019 Apr; 15(4):197-207. PubMed ID: 30814691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bispecific Antibodies: Formats and Areas of Application].
    Vasilenko EA; Mokhonov VV; Gorshkova EN; Astrakhantseva IV
    Mol Biol (Mosk); 2018; 52(3):380-393. PubMed ID: 29989572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.
    Yang F; Wen W; Qin W
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic roles for antibody mixtures.
    Raju TS; Strohl WR
    Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibodies: design, therapy, perspectives.
    Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
    Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Production of Bispecific Antibodies.
    Wang Q; Chen Y; Park J; Liu X; Hu Y; Wang T; McFarland K; Betenbaugh MJ
    Antibodies (Basel); 2019 Aug; 8(3):. PubMed ID: 31544849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-tuning bispecific therapeutics.
    Lim SI
    Pharmacol Ther; 2020 Aug; 212():107582. PubMed ID: 32450189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.